Press Releases

As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. T...

Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), a quality longevity company powered by a pr...

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in ...

•As of July 18, 2026, net asset value (NAV1) per share was $66.16 •As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2. Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up...

FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eli...